HIGH-FLOW NON-INVASIVE VENTILATION (NIV) DEVICES REDUCE THE MORBIDITY AND MORTALITY OF COVID-19. THE OBJECTIVE WAS TO EVALUATE THE USE OF THE NON-INVASIVE VENTILATION DEVICE WITH HIGH-FLOW HELMET CPAP DESIGNED IN PERU IN PATIENTS WITH SEVERE ACUTE RESPIRATORY SYNDROME (COVID-19) HOSPITALIZED IN THE EMERGENCY SERVICES OF FIVE HOSPITALS. PROSPECTIVE MULTICENTER AND CROSS-SECTIONAL OBSERVATIONAL STUDY FROM FIVE HOSPITALS FROM JULY TO AUGUST 2020. 19 PATIENTS WERE RECRUITED AND DIVIDED INTO TWO GROUPS (G-1 N = 10; G-2 N = 9) APPLYING CLINICAL AND GASOMETRIC PARAMETERS AS INDICATORS OF DISEASE EVOLUTION UPON HOSPITAL ADMISSION AND WITHIN 24 HOURS. A PROGRESSIVE INCREASE IN THESE PARAMETERS WAS OBSERVED IN THOSE PATIENTS WHO USED THE NIV CPAP HELMET WITHIN THE FIRST 24 HOURS. IN G-01, IMPROVEMENT WAS EVIDENT IN 90% (N = 9/10): PAO2 (RANGE 48–137; AVERAGE: 82.49 ± 8.07; P-VALUE = 0.008), CO2...

High-flow non-invasive ventilation (NIV) devices reduce the morbidity and mortality of COVID-19. The objective was to evaluate the use of the non-invasive ventilation device with high-flow helmet CPAP designed in Peru in patients with severe acute respiratory syndrome (COVID-19) hospitalized in the emergency services of five hospitals. Prospective multicenter and cross-sectional observational study from five hospitals from July to August 2020. 19 patients were recruited and divided into two groups (G-1 n = 10; G-2 n = 9) applying clinical and gasometric parameters as indicators of disease evolution upon hospital admission and within 24 hours. A progressive increase in these parameters was observed in those patients who used the NIV CPAP helmet within the first 24 hours. In G-01, improvement was evident in 90% (n = 9/10): PaO2 (range 48–137; average: 82.49 ± 8.07; p-value = 0.008), CO2...